Oncology – Breast | Links Medicus Content Curation & Alerts in Medicine

Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomized trials.

15 Oct, 2021 | 02:07h | UTC

Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials – The Lancet Oncology

Commentary on Twitter

@OncoAlert Success of a monoclonal antibody when @ right target – 10 yr benefits of trastuzumab – #EBCTCG meta-analysis (N>13,000):
👉Impressive absolute and relative ~1/3 reduced deaths, ~1/3 recurrences
👉ER-: Recur⬇️ 11%
👉ER+: Recur⬇️ 8%@kevinpunie @prat_aleix @itsnot_pink https://t.co/O1WKcEEuGG

— Nicole Kuderer (@NicoleKuderer) August 4, 2021

Cohort Study: Women treated with radiation therapy for left-sided breast cancer had over twice the risk of subsequent coronary artery disease compared with women treated with radiation therapy for right-sided breast cancer.

1 Oct, 2021 | 10:21h | UTC

Coronary Artery Disease in Young Women After Radiation Therapy for Breast Cancer: The WECARE Study – JACC: CardioOncology

Commentaries:

Left Breast Radiation Therapy Doubles CV Disease Risk vs. Right Breast Radiation Therapy in Young Women – American College of Cardiology

CAD in Young Women After Radiation Therapy for Breast Cancer – American College of Cardiology

Commentary on Twitter

According to a study from #JACCCardioOnc, women with left-sided breast cancer undergoing radiation therapy between 1985 and 2008 had over twice the risk of subsequent #cvCAD compared to women with right-sided breast cancer. Learn more here: https://t.co/5q9tToSSRp #CardioOnc

— American College of Cardiology (@ACCinTouch) September 22, 2021

Systematic Review: Partial breast irradiation versus whole breast radiotherapy for early breast cancer.

15 Sep, 2021 | 08:46h | UTC

Partial breast irradiation versus whole breast radiotherapy for early breast cancer – Cochrane Library

Commentary on Twitter

For women with early-stage #BreastCancer, how does giving radiotherapy to part of the breast compare with giving #radiotherapy to the whole breast? The latest Cochrane Review from @CochraneBCancer brings together nine studies, which involved 15,187 women: https://t.co/fVuSrSDAZM pic.twitter.com/QOufZYSH5I

— Cochrane UK (@CochraneUK) September 3, 2021

Long-term report of study evaluating radiation following surgical excision for good-risk ductal carcinoma in situ.

14 Sep, 2021 | 08:44h | UTC

Randomized Phase III Trial Evaluating Radiation Following Surgical Excision for Good-Risk Ductal Carcinoma In Situ: Long-Term Report From NRG Oncology/RTOG 9804 – Journal of Clinical Oncology

Commentary on Twitter

At 15 years, NRG-RTOG 9804 "good risk" breast #DCIS trial shows advantage of radiation therapy over observation to reduce #breastcancer risk https://t.co/l5OWVOb5Dg
#JCO #BCSM #radonc @NRGOnc; @MSK_RadOnc pic.twitter.com/TPAZRheoHT

— ASCO Publications (@ASCO_pubs) September 10, 2021

Review: neoadjuvant endocrine therapy in clinical practice.

12 Sep, 2021 | 21:34h | UTC

Neoadjuvant Endocrine Therapy in Clinical Practice: A Review – JAMA Oncology (free for a limited period)

Systematic review finds there is insufficient evidence that AI breast cancer screening is accurate enough to replace human scrutiny.

10 Sep, 2021 | 05:12h | UTC

Insufficient evidence that AI breast cancer screening is accurate enough to replace human scrutiny – The BMJ

Original study: Use of artificial intelligence for image analysis in breast cancer screening programmes: systematic review of test accuracy – The BMJ

Commentary on Twitter

A systematic review of #AI for mammography is very disappointing
"Thirty four (94%) of 36 AI systems evaluated in these studies were less accurate than a single radiologist, and all were less accurate than consensus of two or more radiologists"https://t.co/zqFTxojU9J @bmj_latest pic.twitter.com/wylwOsf4ua

— Eric Topol (@EricTopol) September 2, 2021

Cohort study: Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers.

20 Aug, 2021 | 08:39h | UTC

Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study – American Journal of Obstetrics and Gynecology

Commentary on Twitter

For #BRCA1 mutation carriers, longer duration of oral contraceptive use (>10 yr) is associated with a greater reduction in #OvarianCancer risk, and the protection is long term. https://t.co/HrrutgaYKX

— Anna Chichura, MD (@AnnaChichuraMD) July 3, 2021

Oncoplastic breast surgery: A guide to good practice.

19 Aug, 2021 | 08:40h | UTC

Oncoplastic breast surgery: A guide to good practice – European Journal of Surgical Oncology

ASCO Guideline Update: Chemotherapy and Targeted Therapy for Patients with Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor–Negative.

12 Aug, 2021 | 08:52h | UTC

Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor–Negative: ASCO Guideline Update – Journal of Clinical Oncology

ASCO Guideline Update: Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer.

30 Jul, 2021 | 11:51h | UTC

Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Update – Journal of Clinical Oncology

Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline.

30 Jul, 2021 | 11:49h | UTC

Management of the Axilla in Early-Stage Breast Cancer: Ontario Health (Cancer Care Ontario) and ASCO Guideline – Journal of Clinical Oncology

RCT: Duration of adjuvant aromatase-inhibitor therapy in postmenopausal breast cancer.

30 Jul, 2021 | 11:43h | UTC

Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer – New England Journal of Medicine

Commentary on Twitter

In postmenopausal women with hormone-receptor-positive breast cancer who had 5 yrs of AI, extending adjuvant endocrine therapy by 5 years provides no benefit over a 2-year extension but is associated with a greater risk of bone fracturehttps://t.co/YDxeQVu8B9

— K Pavithran (@drkpavithran) July 29, 2021

Systematic review: Breast Reconstruction After Mastectomy.

22 Jul, 2021 | 10:45h | UTC

Breast Reconstruction After Mastectomy – Agency for Healthcare Research and Quality

Global burden of cancer attributable to alcohol consumption – “Globally, an estimated 741.300, or 4·1% of all new cases of cancer in 2020 were attributable to alcohol consumption”.

14 Jul, 2021 | 11:07h | UTC

Global burden of cancer in 2020 attributable to alcohol consumption: a population-based study – The Lancet Oncology

News release: Alcohol consumption linked to more than 740,000 new cancer cases in 2020 – The Lancet

Commentaries: Alcohol caused 740,000 cancer cases globally last year – study – The Guardian AND Expert reaction to study of alcohol and cancer – Science Media Centre

M-A: Pregnancy After Breast Cancer – “These results provide reassuring evidence on the safety of conceiving in BC survivors”.

6 Jul, 2021 | 09:55h | UTC

Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary on Twitter

Honored and excited to share our large #metanalysis presented at #SABCS20 now published in @ASCO_pubs #JCO providing solid and reassuring evidence on fetal and maternal safety of #pregnancy after prior #BreastCancer history@OncoAlert #SurvOnc #bcsm
Link: https://t.co/lgKQDeB2VS pic.twitter.com/rTpFKsrpMc

— Matteo Lambertini, MD PhD (@matteolambe) July 1, 2021

RCT: Similar outcomes with 5 vs. 2 years of zoledronate treatment following adjuvant chemotherapy in early breast cancer.

1 Jul, 2021 | 09:50h | UTC

Outcomes With 5 vs 2 Years of Zoledronate Treatment Following Adjuvant Chemotherapy in Early Breast Cancer – The ASCO Post

Original Study: Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)

RCT: Heart-protecting drugs likely unnecessary for most breast cancer patients undergoing adjuvant treatment.

8 Jun, 2021 | 09:15h | UTC

Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy (PRADA) Extended Follow-Up of a 2×2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol – Circulation

Commentaries: Heart-protecting drugs likely unnecessary for many breast cancer patients – American College of Cardiology

Population-based cohort study suggests increased survival after breast conservation surgery + radiotherapy compared to mastectomy with or without radiotherapy in women with breast cancer.

10 May, 2021 | 00:42h | UTC

Survival After Breast Conservation vs Mastectomy Adjusted for Comorbidity and Socioeconomic Status: A Swedish National 6-Year Follow-up of 48 986 Women – JAMA Surgery

Commentary: Breast-Conserving Surgery+RT Yields Significant Survival Benefits For Early-Stage Breast Cancer – Physician’s Weekly

Commentary on Twitter

Women receiving breast-conserving surgery for #breastcancer fare better than those who take away the whole breast says a new study taking into account comorbidities and socioeconomic background. Superior survival rates support less extensive surgery https://t.co/JEXasP56Di

— JAMA Surgery (@JAMASurgery) May 5, 2021